Baseline Relationships Between Measures of Cognitive Function and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis in ENLIGHTEN: a Phase 3b Study of Ozanimod.


Conference paper


Morrow S, Zivadinov R, DeLuca J, Riolo JV, Cheng C, Wray S, Bass A, Fox E, Riser E, Chaudhry B, Reardon J, Silva D, Naismith RT
Americas Committee for Treatment and Research in Multiple Sclerosis Forum, San Diego, CA, 2023

Cite

Cite

APA
S, M., R, Z., J, D. L., JV, R., C, C., S, W., … RT, N. (2023). Baseline Relationships Between Measures of Cognitive Function and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis in ENLIGHTEN: a Phase 3b Study of Ozanimod. San Diego, CA.

Chicago/Turabian
S, Morrow, Zivadinov R, DeLuca J, Riolo JV, Cheng C, Wray S, Bass A, et al. “Baseline Relationships Between Measures of Cognitive Function and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis in ENLIGHTEN: a Phase 3b Study of Ozanimod.” Americas Committee for Treatment and Research in Multiple Sclerosis Forum. San Diego, CA, 2023.

MLA
S, Morrow, et al. Baseline Relationships Between Measures of Cognitive Function and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis in ENLIGHTEN: a Phase 3b Study of Ozanimod. 2023.